 |
|
|
| |
Cost-Effectiveness of Treating Different Stages of Genotype 1 Hepatitis C Virus (GT1-HCV) With Viekira Pak (Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin Compared to No Treatment in the United States
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
SJ Johnson1, TR Juday2, JC Samp2, SE Marx2, H Parisé1, S Virabhak1, S Saab3
1Medicus Economics, Milton, 2Global Health Economics and Outcomes Research, AbbVie, Mettawa, 3Pfleger Liver Institute, Los Angeles, United States
|
| |
|
|
|
|
|
